SINT vs. CTSO, TELA, ICCM, BDMD, SURG, SRTS, PYPD, APT, TMDIF, and NMTC
Should you be buying Sintx Technologies stock or one of its competitors? The main competitors of Sintx Technologies include Cytosorbents (CTSO), TELA Bio (TELA), IceCure Medical (ICCM), Baird Medical Investment (BDMD), SurgePays (SURG), Sensus Healthcare (SRTS), PolyPid (PYPD), Alpha Pro Tech (APT), Titan Medical (TMDIF), and NeuroOne Medical Technologies (NMTC). These companies are all part of the "medical equipment" industry.
Sintx Technologies vs. Its Competitors
Sintx Technologies (NASDAQ:SINT) and Cytosorbents (NASDAQ:CTSO) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, risk, media sentiment, valuation, institutional ownership, profitability, analyst recommendations and dividends.
Sintx Technologies presently has a consensus target price of $25.00, suggesting a potential upside of 566.67%. Cytosorbents has a consensus target price of $5.50, suggesting a potential upside of 546.91%. Given Sintx Technologies' higher possible upside, equities analysts clearly believe Sintx Technologies is more favorable than Cytosorbents.
Sintx Technologies has higher earnings, but lower revenue than Cytosorbents. Cytosorbents is trading at a lower price-to-earnings ratio than Sintx Technologies, indicating that it is currently the more affordable of the two stocks.
In the previous week, Sintx Technologies had 6 more articles in the media than Cytosorbents. MarketBeat recorded 7 mentions for Sintx Technologies and 1 mentions for Cytosorbents. Sintx Technologies' average media sentiment score of 0.70 beat Cytosorbents' score of 0.00 indicating that Sintx Technologies is being referred to more favorably in the media.
Sintx Technologies has a beta of 0.83, indicating that its stock price is 17% less volatile than the S&P 500. Comparatively, Cytosorbents has a beta of 1.28, indicating that its stock price is 28% more volatile than the S&P 500.
18.4% of Sintx Technologies shares are held by institutional investors. Comparatively, 32.9% of Cytosorbents shares are held by institutional investors. 4.1% of Sintx Technologies shares are held by insiders. Comparatively, 7.3% of Cytosorbents shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Cytosorbents has a net margin of -25.58% compared to Sintx Technologies' net margin of -674.05%. Cytosorbents' return on equity of -111.97% beat Sintx Technologies' return on equity.
Summary
Cytosorbents beats Sintx Technologies on 8 of the 14 factors compared between the two stocks.
Get Sintx Technologies News Delivered to You Automatically
Sign up to receive the latest news and ratings for SINT and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding SINT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Sintx Technologies Competitors List
Related Companies and Tools
This page (NASDAQ:SINT) was last updated on 10/24/2025 by MarketBeat.com Staff
Free SINT Stock Alerts